Clinical Trial Update: Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. [Phase 3]

View source ↗

Summary

Phase III trial of NPB-01 as maintenance therapy for chronic inflammatory demyelinating polyneuropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• NPB-01

Snippet

Sponsor: Nihon Pharmaceutical Co., Ltd | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Status: COMPLETED